PATENT CLAIM ANALYSIS

Application Number: 16020469
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["530", "351000"]

Abstract:
The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Claim (Index 7):
The construct according to any of the preceding claims, wherein said targeting moiety is directed towards a target selected from the group consisting of CD20, Her2, c-Met, EGFR, tenascin C, \u03b1 v \u03b2 3 integrin and CD13.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 94.0
- Lexical Diversity: 2.2069
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14905354', '15883925', '14372730', '15717205', '15278854']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7944860532864284
- 35 USC 102 Novelty (BERT): 0.638894488427114
- Combined Prediction Score: 0.778926896800497
- Mean Citation Score: 506.47091600000016
- Max Citation Score: 751.4879
- Similarity Product: 553.7805500423074

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test